Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...
Recursion Pharmaceuticals has raised $60 million to step up its artificial intelligence-enabled drug discovery activities. The series B equips Recursion to move beyond its initial focus on repurposing ...
Community driven content discussing all aspects of software development from DevOps to design patterns. Recursion in Java gets a bad rap. Experienced developers shun the practice over fears that an ...
In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients Drug discovery research collaboration may initiate up to seven oncology ...
Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results